NASDAQ: TLXTelix Pharmaceuticals Ltd Stock
$10.09+0.15 (+1.51%)
Updated Jun 18, 2026
TLX Price
$10.09
Fair Value Price
N/A
Market Cap
$3.42B
52 Week Low
$6.28
52 Week High
$16.98
P/E
N/A
P/B
11.85x
P/S
4.65x
PEG
N/A
Dividend Yield
N/A
Revenue
$558.19M
Earnings
-$4.78M
Gross Margin
53.1%
Operating Margin
4.43%
Profit Margin
-0.9%
Debt to Equity
1.8
Operating Cash Flow
-$12M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TLX Overview
Telix Pharmaceuticals Limited (TLX) is a commercial-stage biopharmaceutical entity specializing in the creation and distribution of advanced radiopharmaceuticals. Its core mission is to develop both diagnostic agents and therapeutic treatments for cancer and rare diseases across key international markets, including Australia, Belgium, Japan, Switzerland, and the United States. Among its currently available products, Telix offers Illuccix, designed for the management of prostate cancer, and TLX66-CDx, which serves as an imaging agent for osteomyelitis. The company also maintains a robust pipeline of investigational candidates aimed at various conditions: Prostate Cancer: TLX591, a radio antibody-drug conjugate, and TLX592, a candidate for targeted alpha therapy. Renal (Kidney) Cancer: TLX250-CDx, intended for both diagnosis and treatment, and TLX250, specifically for clear cell renal cell carcinoma. Brain Cancer: This includes TLX101-CDx and TLX101, which targets glioblastoma. Bone Marrow Conditioning: TLX66-CDx and TLX66 are being explored. Soft Tissue Sarcoma: TLX300-CDx and TLX300 are under development for diagnosis and treatment. Founded in 2015, Telix Pharmaceuticals Limited is based in North Melbourne, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TLX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TLX
Ranked#199 of 465
Ranked#199 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important TLX news, forecast changes, insider trades & much more!
TLX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLX is poor value based on its book value relative to its share price (11.85x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
TLX's cash burn is expected to be positive in the next year ($7.96M), after accounting for decreasing cash burn (73.35%)
Interest Coverage Financials
TLX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 30 more TLX due diligence checks available for Premium users.
Valuation
TLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.85x
Industry
4.95x
TLX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
TLX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TLX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$781.2M
Liabilities
$502.4M
Debt to equity
1.8
TLX's short-term assets ($229.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLX's long-term liabilities ($359.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
TLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLX vs Biotech Stocks
Telix Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.